Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic...

Area of Science:

• Pediatric Rheumatology
• Clinical Trial Methodology
• Disease Activity Measurement

Background:

• Assessing disease activity in pediatric rheumatic conditions like enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (jPsA) is crucial for effective treatment.
• The Juvenile Spondyloarthritis Disease Activity Index (JSpADA) is a potential tool for this purpose.

Purpose of the Study:

• To validate the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) in children diagnosed with ERA or jPsA.
• To assess JSpADA's convergent validity, discriminant validity, and responsiveness within a prospective clinical trial setting.

Main Methods:

• The JUNIPERA study (NCT03031782), a phase III trial, evaluated secukinumab in children with ERA and jPsA.
• JSpADA validity was assessed by correlating it with established measures (JADAS10, cJADAS10, PGA) and analyzing its performance in distinguishing active vs. inactive disease and its responsiveness to treatment changes.

Main Results:

• JSpADA demonstrated moderate to good convergent validity with JADAS10, cJADAS10, and PGA at week 12 (Spearman ρ > 0.4).
• JSpADA scores were significantly higher in patients with active disease compared to inactive disease (P < 0.001).
• JSpADA showed responsiveness to clinical disease activity changes from week 12 to week 52, with significant differences observed between improving, worsening, and stable disease groups (P < 0.001).

Conclusions:

• The Juvenile Spondyloarthritis Disease Activity Index (JSpADA) is validated as a reliable measure of disease activity for pediatric patients with ERA and jPsA.
• JSpADA's performance was consistent across both ERA and jPsA patient subgroups within the prospective clinical trial setting.